Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
July 03 2023 - 6:30PM
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, will report financial results for the
first quarter fiscal year 2023 on Thursday, July 6, 2023. The
Company has scheduled a conference call for that same day, July 6,
2023 at 11:00am ET (16:00pm BST) to discuss the results of the
quarter.
Interested parties can access the call by dialing: |
|
US Toll Free: |
1-844-861-5499 |
|
International Toll: |
1-412-317-6581 |
|
Ireland Toll: |
014311269 |
|
Ireland Toll Free: |
1800932830 |
Please ask to be joined into the Trinity Biotech call. |
|
A simultaneous webcast of the call can be
accessed
at:https://event.choruscall.com/mediaframe/webcast.html?webcastid=C83esXnK
A replay of the call can be accessed until July 13, 2023 by
dialing: |
|
US Toll Free: |
1-877-344-7529 |
|
International Toll: |
1-412-317-0088 |
|
Canada Free Toll: |
1-855-669-9658 |
|
Replay Code: |
6140640 |
|
|
|
To access the replay using an international dial-in number,
please see the link
below:https://services.choruscall.com/ccforms/replay.html
A webcast of the call will be available for 30 days at:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=C83esXnK
Replays will be available 1 hour after the end of the
conference.
Certain statements made in this release that are
not historical are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The
words “estimate”, “project”, “intend”, “expect”, “believe” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve known
and unknown risks and uncertainties. Many factors could cause
the actual results, performance or achievements of Trinity Biotech
to be materially different from any future results, performance or
achievements that may be expressed or implied by such
forward-looking statements, including, but not limited to, the
results of research and development efforts, risks associated with
the outbreak and global spread of the coronavirus (COVID-19), the
effect of regulation by the U.S. Food and Drug Administration and
other agencies, the impact of competitive products, product
development commercialization and technological difficulties.
For additional information regarding these and other risks and
uncertainties associated with Trinity Biotech’s business, reference
is made to our reports filed from time to time with the U.S.
Securities and Exchange Commission. We undertake no
obligation to update or revise any forward-looking statements for
any reason.
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com.
ContactJohn GillardTrinity Biotech
plc(353)-1-2769800
Joe DiazLytham Partners, LLCInvestor
Relations(1)-602-889-9700E-mail:
investorrelations@trinitybiotech.com
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2024 to May 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From May 2023 to May 2024